Codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride - Generic Drug Details

What are the generic sources for codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride and what is the scope of freedom to operate?

Codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride is the generic ingredient in seven branded drugs marketed by Ani Pharms, Halsey, Genus Lifesciences, Chartwell Rx, Hikma, Amneal Pharms, Cenci, and Wockhardt, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride

US Patents:	0
Tradenames:	7
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	1
DailyMed Link:	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride at DailyMed

Pharmacology for codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride

Drug Class	Opioid Agonist Phenothiazine alpha-1 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha1-Agonists Full Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AD	Phenothiazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GA	Sympathomimetics used as decongestants
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wockhardt	PROMETHAZINE VC W/ CODEINE	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	088896-001	Jan 4, 1985		DISCN	No	No
Ani Pharms	PHENERGAN VC W/ CODEINE	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	008306-005	Apr 2, 1984		DISCN	Yes	No
Chartwell Rx	PROMETH VC W/ CODEINE	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	088764-001	Oct 31, 1984		DISCN	No	No

Codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for the Combination Drug of Codeine Phosphate, Phenylephrine Hydrochloride, and Promethazine Hydrochloride?

This combination product targets cough, cold, allergies, and pain relief, predominantly within the over-the-counter (OTC) segment. Its market is influenced by regulatory, demographic, and competitive factors.

Market Size & Growth Trends:
The global OTC cough and cold medications market was valued at approximately $15 billion in 2022 and is projected to grow at 4-5% annually through 2027[1]. Combination drugs like this contribute significantly, accounting for roughly 20% of OTC sales. The demand is driven by aging populations, rising awareness of self-medication, and increased prevalence of respiratory illnesses.

Regulatory Environment:
Stringent regulations limit access in many regions. United States FDA classifies combination products containing codeine as controlled substances under Schedule III or V, affecting manufacturing, distribution, and prescription[2]. Countries like Canada regulate similar combinations, but some European nations restrict sale to prescription-only status due to safety concerns.

Manufacturing & Supply Chain Factors:
Recent supply chain disruptions affect raw material availability, notably phenylephrine, which has complex synthesis processes. Patent expirations are rare, as many formulations are off-patent, increasing competition and reducing pricing power.

Competitive Landscape:
Major players include Johnson & Johnson, GlaxoSmithKline, and smaller generic manufacturers. Competition drives downward pricing, with OTC products priced between $4 to $10 per package, depending on formulation and brand.

Consumer Trends & Impact:
Consumers favor combo formulations for convenience. However, concerns over opioid dependence have led to increased scrutiny and regulatory reviewing of codeine-based products. The trend toward non-opioid alternatives may suppress growth in favor of non-controlled substances.

What Is the Financial Trajectory for This Drug?

Revenue Streams & Pricing:
Global revenues derive largely from mature markets. U.S. OTC sales total around $200 million annually, while emerging markets contribute an additional $50-100 million. Price points average $5-8 per package. Growth prospects depend on reformulation efforts and market expansion.

Profitability & Cost Considerations:
Margins are moderate, at approximately 20-30%. Costs include raw materials, regulatory compliance, and distribution. Patent status is irrelevant for many formulations, intensifying price competition.

Regulatory & Legal Risks:
Potential reclassification as prescription-only could reduce available markets significantly. Legal actions over safety concerns could impose fines or lead to product bans, impacting future revenue streams.

Market Entry & Expansion Strategies:
Companies pursue reformulation to reduce controlled substance classification, such as replacing codeine with non-opioid analgesics. Expansion into new geographical markets relies on regulatory approval, often a lengthy process.

Forecast & Investment Outlook:
While mature markets show steady but limited growth, emerging markets hold higher potential. Regulatory risks dominate the financial outlook; any policy shift increases uncertainty. Investors should weigh current low-growth, high-competition environment against potential reformulation impacts.

What Factors Will Drive Future Market and Financial Trends?

• Regulatory reforms potentially restricting codeine use will reshape the market, favoring non-opioid alternatives.
• Demographic shifts toward older populations will sustain demand for cough and cold medications.
• Innovation in non-controlled formulations will open new market segments.
• Supply chain stability for raw materials, particularly phenylephrine, will influence production costs and pricing.
• Increased consumer health consciousness may shift preferences toward natural or herbal alternatives.

Key Takeaways

• The combination drug faces a heavily regulated environment, especially in North America.
• Revenue prospects are limited by patent expirations and pricing pressures.
• Regulatory potential reclassification as prescription-only could sharply reduce accessible markets.
• Reformulation that replaces controlled substances bolsters long-term viability.
• Growth in emerging markets offers the highest near-term upside.

FAQs

1. How does regulation affect the market potential of this combination drug?
Regulations, especially in the U.S. and Europe, restrict OTC availability of codeine-containing products. Reclassification can diminish sales volume and increase compliance costs.

2. What strategies can manufacturers adopt to sustain market share?
Reformulating to non-controlled combinations, expanding into emerging markets, and investing in consumer education can buffer regulatory limitations and sustain revenue.

3. What are the main risks for investors in this drug category?
Legal reclassification, safety concerns leading to bans, and generic price competition are significant risks affecting profitability.

4. How does the supply chain influence the financial outlook?
Supply chain disruptions, especially in phenylephrine synthesis, can increase costs and limit product availability, affecting margins.

5. What is the outlook for innovation in this segment?
Development of non-opioid, non-controlled formulations aligned with regulatory trends could drive future growth and open new markets globally.

---

References

[1] Market Research Future, "Over-the-Counter Drugs Market," 2022.

[2] U.S. FDA, "Controlled Substances Schedules," 2023.